Radionuclides and carrier molecules for therapy.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Physics in Medicine and Biology

• Publication date

  1996-10-01

• Fields of study

  Medicine, Physics

• Identifiers
  DOI 10.1088/0031-9155/41/10/004PMID 8912370
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Radionuclide therapy revisited

  2005cited by this paper
• Targeted therapy using alpha emitters.

  1996cited by this paper
• Imaging technologies for radionuclide dosimetry.

  1996cited by this paper
• Targeted radiotherapy using Auger electron emitters.

  1996cited by this paper
• Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides.

  1995cited by this paper
• Radiolabeling kit/generator for 5‐radiohalogenated uridines

  1994cited by this paper
• 212Pb/212Bi-EDTMP : synthesis and biodistribution of a novel bone seeking alpha-emitting radiopharmaceutical

  1994cited by this paper
• Radiotoxicity of platinum-195m-labeled trans-platinum (II) in mammalian cells.

  1994cited by this paper
• Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer

  1994cited by this paper
• Merrill C. Sosman Lecture. The Auger process: a therapeutic promise?

  1993cited by this paper
• The feasibility of 225 Ac as a source of α‐particles in radioimmunotherapy

  1993cited by this paper
• Measuring astatine-211 distributions with SPECT.

  1993cited by this paper
• Radiobiological modeling of combined targeted 131I therapy and total body irradiation for treatment of disseminated tumors of differing radiosensitivity.

  1993cited by this paper
• The feasibility of 225Ac as a source of alpha-particles in radioimmunotherapy.

  1993cited by this paper
• G2M arrest and apoptosis in murine T lymphoma cells following exposure to 212Bi alpha particle irradiation.

  1993cited by this paper
• Biological effects of the Auger emitter iodine-125: a review. Report No. 1 of AAPM Nuclear Medicine Task Group No. 6.

  1992cited by this paper
• Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer.

  1992cited by this paper
• 1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation.

  1992cited by this paper
• 211At-methylene blue for targeted radiotherapy of human melanoma xenografts: treatment of cutaneous tumors and lymph node metastases.

  1992cited by this paper
• Therapeutic radionuclides: production and decay property considerations.

  1991cited by this paper
• Nonuniformity of tumor dose in radioimmunotherapy.

  1990cited by this paper
• Labeling of human IgG with rhodium-105 using a new pentadentate bifunctional ligand.

  1990cited by this paper
• Similar lethal effect in mammalian cells for two radioisotopes of copper with different decay schemes, 64Cu and 67Cu.

  1989cited by this paper
• Macroscopic dosimetry for radioimmunotherapy: nonuniform activity distributions in solid tumors.

  1989cited by this paper
• Labeling of proteins with 105Rh

  1989cited by this paper
• Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity.

  1989cited by this paper
• Radioimmunotherapy with alpha-particle-emitting immunoconjugates.

  1988cited by this paper
• An improved generator for the production of 212Pb and 212Bi from 224Ra.

  1988cited by this paper
• Astatination of proteins using an N-succinimidyl tri-n-butylstannyl benzoate intermediate.

  1988cited by this paper
• 105Rh as a potential radiotherapeutic agent.

  1988cited by this paper
• Radiobiologic implications of the microscopic distribution of energy from radionuclides.

  1987cited by this paper
• Potential diagnostic and therapeutic agents for malignant melanoma: Synthesis of heavy radiohalogenated derivatives of methylene blue by electrophilic and nucleophilic methods

  1986cited by this paper
• Dosimetric aspects of radiolabeled antibodies for tumor therapy.

  1986cited by this paper
• Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy.

  1986cited by this paper
• Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies.

  1984cited by this paper
• The role of subcellular localization in assessing the cytotoxicity of iodine-125 labeled iododeoxyuridine, iodotamoxifen, and iodoantipyrine

  1981cited by this paper
• Absorption of 20-eV to 50,000-eV electron beams in air and plastic.

  1969cited by this paper

• Iodinated Copper–Cysteamine Nanoparticles as Radiosensitizers for Tumor Radiotherapy

  2025influential citation
• Results from an EANM survey on time estimates and personnel responsible for main tasks in molecular radiotherapy dosimetry

  2023cites this paper
• Current and upcoming radionuclide therapies in the direction of precision oncology: A narrative review

  2023cites this paper
• Radioimmunotherapy of glioblastoma multiforme - current status and future prospects.

  2021cites this paper
• Evaluation of Dosimetric Parameters for Tumor Therapy with 177Lu and 90Y Radionuclides in Gate Monte Carlo Code

  2021cites this paper
• Development of a portable gamma imaging system for absorbed radiation dose control in molecular radiotherapy

  2019cites this paper
• Radioactive Main Group and Rare Earth Metals for Imaging and Therapy.

  2018cites this paper
• Cancer theranostic applications of lipid-based nanoparticles.

  2018cites this paper
• Techniques for Loading Technetium-99m and Rhenium-186/188 Radionuclides into Preformed Liposomes for Diagnostic Imaging and Radionuclide Therapy.

  2017cites this paper
• Bioinspired nanotheranostics for cancer management

  2017cites this paper
• Separation of 103Ru from a proton irradiated thorium matrix: A potential source of Auger therapy radionuclide 103mRh

  2017cites this paper
• Voxel-level dosimetry of 177Lu-octreotate: from phantoms to patients

  2017cites this paper
• Liposomes

  2017cites this paper
• A comparison between track-structure, condensed-history Monte Carlo simulations and MIRD cellular S-values

  2017cites this paper
• Moving Forward: Expected Opportunities for the Development of New Therapeutic Agents Based on Nanotechnologies

  2016cites this paper
• Convolution and model-based dose calculation methods in radionuclide and external-beam photon therapy

  2016cites this paper
• Validation of 64 Cu-ATSM damaging DNAvia high-LETAuger electron emission

  2015cites this paper
• Validation of 64Cu-ATSM damaging DNA via high-LET Auger electron emission

  2015cites this paper
• Estudo de análogo da subtância P para desenvolvimento de radiofármaco com aplicação na terapia de tumores cerebrais

  2015cites this paper
• Interventional therapy for human breast cancer in nude mice with 131I gelatin microspheres (131I-GMSs) following intratumoral injection

  2014cites this paper
• Biological carrier molecules of radiopharmaceuticals for molecular cancer imaging and targeted cancer therapy.

  2014cites this paper
• Therapeutic radionuclides in nuclear medicine: current and future prospects

  2014cites this paper
• Estudo da marcação com Indio-111 e Gálio-68 de derivados da bombesina e avaliação das propriedades biológicas para aplicação em SPECT e PET

  2014cites this paper
• Image-guided interventional therapy for cancer with radiotherapeutic nanoparticles.

  2014cites this paper
• Estudo da marcação com lutécio-177 de derivados da bombesina e avaliação das propriedades biológicas

  2014influential citation
• Integral Radionuclide Activation Yield and Evaluated Cross Section Data for Proton Induced Reactions with Cd for Practical Applications

  2014cites this paper
• Purification of 89Sr source obtained from 89Y(n, p) 89Sr by ion-exchange chromatography using tri-sodium tri-meta phosphate (SMP) as eluant

  2014cites this paper
• Calculation of excitation functions for the production of Cu and Co medical isotopes

  2013cites this paper
• Production parameters of the therapeutic 105Rh radionuclide using medium energy cyclotron

  2012cites this paper
• Brachytherapy using injectable seeds that are self-assembled from genetically encoded polypeptides in situ.

  2012cites this paper
• A Unique Matched Quadruplet of Terbium Radioisotopes for PET and SPECT and for α- and β−-Radionuclide Therapy: An In Vivo Proof-of-Concept Study with a New Receptor-Targeted Folate Derivative

  2012cites this paper
• Lipid- and Polymer-Based Nanostructures for Cancer Theranostics

  2012cites this paper
• Chemoradionuclide therapy with 186Re-labeled liposomal doxorubicin in combination with radiofrequency ablation for effective treatment of head and neck cancer in a nude rat tumor xenograft model.

  2011cites this paper
• Chemoradionuclide Therapy with 186Re-Labeled Liposomal Doxorubicin: Toxicity, Dosimetry, and Therapeutic Response

  2011cites this paper
• Targeted endoradiotherapy using nucleotides.

  2011cites this paper
• Utility of γH2AX as a molecular marker of DNA double-strand breaks in nuclear medicine: applications to radionuclide therapy employing auger electron-emitting isotopes.

  2011cites this paper
• Nuclear Medicine Techniques for Pain Management

  2011cites this paper
• Post-lumpectomy intracavitary retention and lymph node targeting of 99mTc-encapsulated liposomes in nude rats with breast cancer xenograft

  2011cites this paper
• Cyclotron production of the 105,106mAg, 100,101Pd, 100,101m,105Rh radionuclides by natPd(p,x) nuclear processes

  2010cites this paper
• Skeletal dosimetry in a voxel-based rat phantom for internal exposures to photons and electrons.

  2010cites this paper
• CT-PET guided target delineation in head and neck cancer and implications for improved outcome

  2010cites this paper
• External and internal radiation therapy: past and future directions.

  2010cites this paper
• The public acceptance of nanomedicine: a personal perspective.

  2009cites this paper
• Radioactive liposomes.

  2009cites this paper
• Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211.

  2009cites this paper
• [(186)Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model.

  2009cites this paper
• Targeted radionuclide therapy: theoretical study of the relationship between tumour control probability and tumour radius for a 32P/33P radionuclide cocktail

  2008cites this paper
• Subcellular S-factors for low-energy electrons: A comparison of Monte Carlo simulations and continuous-slowing-down calculations

  2008cites this paper
• Intraoperative 186 Re-Liposome RadionuclideTherapy in a Head and Neck Squamous Cell Carcinoma Xenograft Positive Surgical MarginModel

  2008cites this paper
• Imaging of 186Re-liposome therapy in ovarian cancer xenograft model of peritoneal carcinomatosis

  2008cites this paper
• Intraoperative 186Re-Liposome Radionuclide Therapy in a Head and Neck Squamous Cell Carcinoma Xenograft Positive Surgical Margin Model

  2008cites this paper
• Targeted Radionuclide Tumor Therapy

  2008cites this paper
• Choice of Radionuclides and Radiolabelling Techniques

  2008cites this paper
• Production cross-sections for the residual radionuclides from the natCd(p, x) nuclear processes

  2008cites this paper
• Hyperpolarized (89)Y offers the potential of direct imaging of metal ions in biological systems by magnetic resonance.

  2007cites this paper
• Pincer complexes of N-heterocyclic carbenes. Potential uses as pharmaceuticals

  2007cites this paper
• 14 Biologically targeted radionuclide therapy

  2007cites this paper
• Small compounds for 'targeted radiotherapy

  2007cites this paper
• Potential use of drug carried-liposomes for cancer therapy via direct intratumoral injection.

  2006cites this paper
• Novel Approach in Radionuclide Tumor Therapy: Dose Enhancement by High Z-Element Contrast Agents

  2006cites this paper
• 64Cu production, ligands and biomedical applications

  2006cites this paper
• Intratumoral Administration of Rhenium-188-Labeled Pullulan Acetate Nanoparticles (PAN) in Mice Bearing CT-26 Cancer Cells for Suppression of Tumor Growth

  2006cites this paper
• A comparison of PET imaging characteristics of various copper radioisotopes

  2005cites this paper
• Prospects and problems in the production of 143Pr for radionuclide therapy applications

  2005cites this paper
• Absorbed dose estimates at the cellular level for 131I.

  2005cites this paper
• Anticancer activity of modified somatostatin analogs

  2005cites this paper
• Absorbed dose estimates at the cellular level for 186Re and 188Re

  2005cites this paper
• Radioimmunotherapy with engineered antibodies

  2004cites this paper
• Modelling of metastatic cure after radionuclide therapy: influence of tumor distribution, cross-irradiation, and variable activity concentration.

  2004cites this paper
• Experimental cross sections for charged particle production of the therapeutic radionuclide 111Ag and its PET imaging analogue 104m,gAg

  2004cites this paper
• A limiting factor for the progress of radionuclide-based cancer diagnostics and therapy Availability of suitable radionuclides

  2004cites this paper
• Performance of coincidence imaging with long-lived positron emitters as an alternative to dedicated PET and SPECT

  2004cites this paper
• Theoretical study of the influence of a heterogeneous activity distribution on intratumoral absorbed dose distribution.

  2004cites this paper
• Tumour therapy with radionuclides: assessment of progress and problems.

  2003cites this paper
• Beta dose-rate distributions in microscopic spherical tumors for intraperitoneal radioimmunotherapy.

  2003cites this paper
• Production, PET performance and dosimetric considerations of 134Ce/134La, an Auger electron and positron-emitting generator for radionuclide therapy

  2002cites this paper
• Production, PET performance and dosimetric considerations of 134Ce/134La, an Auger electron and positron-emitting generator for radionuclide therapy.

  2002cites this paper
• Generation of lead-212 and radioimmunoconjugates for use in cancer therapy and the ‘emanating power’ of stearates

  2001cites this paper
• ESR dosimetry of 89 Sr and 153 Sm in bone

  2001cites this paper
• ESR dosimetry of 89Sr and 153Sm in bone.

  2001cites this paper
• Quantitative imaging with PET: Performance and applications of bromine-76, iron-52, indium-110m and lanthanum-134

  2001cites this paper
• sources and effects of ionizing radiation

  2000cites this paper
• Therapeutic radiopharmaceuticals.

  2000cites this paper
• Dosimetric Principles of Targeted Radiotherapy

  2000cites this paper
• 114mIn, a candidate for radionuclide therapy: low-energy cyclotron production and labeling of DTPA-D-phe-octreotide.

  2000cites this paper
• Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.

  1999cites this paper
• Positron emission tomography and radioimmunotargeting--general aspects.

  1999cites this paper
• Positron emission tomography and radioimmunotargeting--aspects of quantification and dosimetry.

  1999cites this paper
• LIPOSOMES AS CARRIERS OF RADIONUCLIDES: FROM IMAGING TO THERAPY

  1999cites this paper
• Radioimmunotherapy with alpha-emitting nuclides

  1998cites this paper
• Microdosimetry and radiocurability: modelling targeted therapy with -emitters

  1996cites this paper
• Microdosimetry and radiocurability: modelling targeted therapy with -emitters

  1996cites this paper
• Copper radionuclides and radiopharmaceuticals in nuclear medicine.

  1996cites this paper
• Microdosimetry and radiocurability: modelling targeted therapy with beta-emitters.

  1996cites this paper
• Acta Universitatis Upsaliensis Uppsala 2016

  year unknowncites this paper